Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly losses of $(3.25) per share which beat the analyst consensus estimate of $(3.60) by 9.72 percent. This is a 24.52 percent decrease over losses of $(2.61) per share from the same period last year. The company reported quarterly sales of $311.337 million which beat the analyst consensus estimate of $302.268 million by 3.00 percent. This is a 126.84 percent increase over sales of $137.250 million the same period last year.